中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.022 seconds)

    Methods of treating asthma
    1.
    发明申请
    Methods of treating asthma 审中-公开
    治疗哮喘的方法

    公开(公告)号：US20050164323A1

    公开(公告)日：2005-07-28

    申请号：US11022327

    申请日：2004-12-22

    Applicant: Divya Chaudhary ,  Marion Kasaian ,  Cara Williams ,  Suzana Marusic ,  Robert Czerwinski

    Inventor： Divya Chaudhary ,  Marion Kasaian ,  Cara Williams ,  Suzana Marusic ,  Robert Czerwinski

    IPC: A61K38/00 ,  C12N5/08 ,  C12Q1/48 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/53

    CPC classification number: C12Q1/485 ,  G01N33/5047 ,  G01N2500/00 ,  G01N2800/122

    Abstract: Methods for agents useful for treating asthma are disclosed. The methods include screening for agents that inhibit the production of a PKC-θ protein, as well as for agents that inhibit the kinase activity of a PKC-θ protein, or a functional fragment thereof, wherein such agents are useful for treating asthma. The methods also include screening for agents that inhibit the production of a reporter gene product encoded by a nucleic acid sequence operably linked to a PKC-θ promoter. Also disclosed are methods of treating asthma that include administering an agent that inhibits the production of a functional PKC-θ protein or the kinase activity of a PKC-θ protein or a functional fragment thereof. An isolated mast cell lacking expression of endogenous PKC-θ is also disclosed.

    Abstract translation: 公开了可用于治疗哮喘的药剂的方法。 所述方法包括筛选抑制PKC-θ蛋白的产生的试剂，以及抑制PKC-θ蛋白或其功能片段的激酶活性的试剂，其中所述试剂可用于治疗哮喘。 所述方法还包括筛选抑制由与PKC-θ启动子可操作地连接的核酸序列编码的报告基因产物的产物。 还公开了治疗哮喘的方法，其包括施用抑制功能性PKC-θ蛋白产生的药物或PKC-θ蛋白或其功能片段的激酶活性。 还公开了缺乏内源性PKC-θ表达的分离的肥大细胞。

    PD-1, A Receptor for B7-4, and Uses Therefor
    4.
    发明申请
    PD-1, A Receptor for B7-4, and Uses Therefor 审中-公开

    公开(公告)号：US20110033884A1

    公开(公告)日：2011-02-10

    申请号：US12761704

    申请日：2010-04-16

    Applicant: Clive Wood ,  Gordon J. Freeman ,  Divya Chaudhary

    Inventor： Clive Wood ,  Gordon J. Freeman ,  Divya Chaudhary

    IPC: C12Q1/02

    CPC classification number: G01N33/505 ,  G01N33/5052 ,  G01N33/6863 ,  G01N2333/70532 ,  G01N2333/912

    Abstract: Disclosed is a method for modulating an immune response by modulating signaling via PD-1. The immune response may be downregulated by increasing signaling via PD-1, or may be upregulated by decreasing signaling via PD-1. Agents which are useful for stimulating signaling via PD-1 to downregulate an immune response include an activating antibody that recognizes PD-1, a form of B7-4 that binds to an inhibitory receptor, and a small molecule that binds to PD-1. Agents which are useful for inhibiting signaling via PD-1 to upregulate an immune response include a blocking antibody that recognizes PD-1, a non-activating form of B7-4, an antibody that recognizes B7-4, and a soluble form of PD-1. Also disclosed is a method for modulating the interaction of B7-4 with an inhibitory receptor on an immune cell. The method comprises contacting an antigen presenting cell which expresses B7-4 with an agent such as a form of B7-4, a form of PD-1, or an agent that modulates the interaction of B7-4 and PD-1. Also disclosed is a method for inhibiting activation of an immune cell via a non-apoptotic mechanism by increasing the activity or expression of PD-1 in the immune cell. The disclosed methods for modulating an immune response are useful, for instance as therapeutic treatment of a subject with conditions that would benefit from immune response modulation. For instance, a condition such as a tumor, a neurological disease, or an immunosuppressive disease, would be treated by upregulating an immune response, and conditions such as a transplant, an allergy, or an autoimmune disorder would benefit from downregulation of an immune response. Assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule are also disclosed. Further disclosed are a vaccine and also other compositions which contain agents that modulate signaling via PD-1.

    PD-1, a receptor for B7-4, and uses therefor
    8.
    发明申请
    PD-1, a receptor for B7-4, and uses therefor 有权

    公开(公告)号：US20080274490A1

    公开(公告)日：2008-11-06

    申请号：US11519186

    申请日：2006-09-11

    Applicant: Clive R. Wood ,  Gordon J. Freeman ,  Divya Chaudhary

    Inventor： Clive R. Wood ,  Gordon J. Freeman ,  Divya Chaudhary

    IPC: C12Q1/02

    CPC classification number: G01N33/505 ,  G01N33/5052 ,  G01N33/6863 ,  G01N2333/70532 ,  G01N2333/912

    Abstract: Disclosed is a method for modulating an immune response by modulating signaling via PD-1. The immune response may be downregulated by increasing signaling via PD-1, or may be upregulated by decreasing signaling via PD-1. Agents which are useful for stimulating signaling via PD-1 to downregulate an immune response include an activating antibody that recognizes PD-1, a form of B7-4 that binds to an inhibitory receptor, and a small molecule that binds to PD-1. Agents which are useful for inhibiting signaling via PD-1 to upregulate an immune response include a blocking antibody that recognizes PD-1, a non-activating form of B7-4, an antibody that recognizes B7-4, and a soluble form of PD-1. Also disclosed is a method for modulating the interaction of B7-4 with an inhibitory receptor on an immune cell. The method comprises contacting an antigen presenting cell which expresses B7-4 with an agent such as a form of B7-4, a form of PD-1, or an agent that modulates the interaction of B7-4 and PD-1. Also disclosed is a method for inhibiting activation of an immune cell via a non-apoptotic mechanism by increasing the activity or expression of PD-1 in the immune cell. The disclosed methods for modulating an immune response are useful, for instance as therapeutic treatment of a subject with conditions that would benefit from immune response modulation. For instance, a condition such as a tumor, a neurological disease, or an immunosuppressive disease, would be treated by upregulating an immune response, and conditions such as a transplant, an allergy, or an autoimmune disorder would benefit from downregulation of an immune response. Assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule are also disclosed. Further disclosed are a vaccine and also other compositions which contain agents that modulate signaling via PD-1.

Patent Agency Ranking